JP6290781B2 - ［（３−ヒドロキシピリジン−２−カルボニル）アミノ］アルカン酸、エステル及びアミドの製造方法 - Google Patents

［（３−ヒドロキシピリジン−２−カルボニル）アミノ］アルカン酸、エステル及びアミドの製造方法 Download PDF

Info

Publication number
JP6290781B2
JP6290781B2 JP2014514536A JP2014514536A JP6290781B2 JP 6290781 B2 JP6290781 B2 JP 6290781B2 JP 2014514536 A JP2014514536 A JP 2014514536A JP 2014514536 A JP2014514536 A JP 2014514536A JP 6290781 B2 JP6290781 B2 JP 6290781B2
Authority
JP
Japan
Prior art keywords
acid
heteroaryl
branched
aryl
linear
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014514536A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014522409A (ja
Inventor
エム．ランシエル クリストファー
エム．ランシエル クリストファー
ゴリン ボリス
ゴリン ボリス
オウデネス ジャン
オウデネス ジャン
エドワード ディクソン クレイグ
エドワード ディクソン クレイグ
クイグボ ル アラン
クイグボ ル アラン
デンスモア コップ ジェームス
デンスモア コップ ジェームス
マイケル ジャヌスズ ジョン
マイケル ジャヌスズ ジョン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akebia Therapeutics Inc
Original Assignee
Akebia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akebia Therapeutics Inc filed Critical Akebia Therapeutics Inc
Publication of JP2014522409A publication Critical patent/JP2014522409A/ja
Application granted granted Critical
Publication of JP6290781B2 publication Critical patent/JP6290781B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/803—Processes of preparation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80—Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82—Metals of the platinum group
    • B01J2531/824—Palladium

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Materials Engineering (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Curing Cements, Concrete, And Artificial Stone (AREA)
JP2014514536A 2011-06-06 2012-06-05 ［（３−ヒドロキシピリジン−２−カルボニル）アミノ］アルカン酸、エステル及びアミドの製造方法 Active JP6290781B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161493536P 2011-06-06 2011-06-06
US61/493,536 2011-06-06
PCT/US2012/040833 WO2012170377A1 (en) 2011-06-06 2012-06-05 Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018020595A Division JP6510094B2 (ja) 2011-06-06 2018-02-08 ［（３−ヒドロキシピリジン−２−カルボニル）アミノ］アルカン酸、エステル及びアミドの製造方法

Publications (2)

Publication Number Publication Date
JP2014522409A JP2014522409A (ja) 2014-09-04
JP6290781B2 true JP6290781B2 (ja) 2018-03-07

Family

ID=47262177

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2014514536A Active JP6290781B2 (ja) 2011-06-06 2012-06-05 ［（３−ヒドロキシピリジン−２−カルボニル）アミノ］アルカン酸、エステル及びアミドの製造方法
JP2018020595A Active JP6510094B2 (ja) 2011-06-06 2018-02-08 ［（３−ヒドロキシピリジン−２−カルボニル）アミノ］アルカン酸、エステル及びアミドの製造方法
JP2019070979A Active JP6816195B2 (ja) 2011-06-06 2019-04-03 ［（５−（ハロフェニル）−３−ヒドロキシピリジン−２−カルボニル）−アミノ］アルカン酸誘導体の調製における中間体としての５−（（ハロフェニル）−３−ハロ−ピリジン−２−イル）−ニトリル誘導体
JP2020213442A Active JP7039682B2 (ja) 2011-06-06 2020-12-23 ［（５－（ハロフェニル）－３－ヒドロキシピリジン－２－カルボニル）－アミノ］アルカン酸誘導体の調製における中間体としての５－（（ハロフェニル）－３－ハロ－ピリジン－２－イル）－ニトリル誘導体
JP2022035813A Active JP7284309B2 (ja) 2011-06-06 2022-03-09 ［（５－（ハロフェニル）－３－ヒドロキシピリジン－２－カルボニル）－アミノ］アルカン酸誘導体の調製における中間体としての５－（（ハロフェニル）－３－ハロ－ピリジン－２－イル）－ニトリル誘導体
JP2023081959A Active JP7685552B2 (ja) 2011-06-06 2023-05-18 ［（５－（ハロフェニル）－３－ヒドロキシピリジン－２－カルボニル）－アミノ］アルカン酸誘導体の調製における中間体としての５－（（ハロフェニル）－３－ハロ－ピリジン－２－イル）－ニトリル誘導体

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2018020595A Active JP6510094B2 (ja) 2011-06-06 2018-02-08 ［（３−ヒドロキシピリジン−２−カルボニル）アミノ］アルカン酸、エステル及びアミドの製造方法
JP2019070979A Active JP6816195B2 (ja) 2011-06-06 2019-04-03 ［（５−（ハロフェニル）−３−ヒドロキシピリジン−２−カルボニル）−アミノ］アルカン酸誘導体の調製における中間体としての５−（（ハロフェニル）−３−ハロ−ピリジン−２−イル）−ニトリル誘導体
JP2020213442A Active JP7039682B2 (ja) 2011-06-06 2020-12-23 ［（５－（ハロフェニル）－３－ヒドロキシピリジン－２－カルボニル）－アミノ］アルカン酸誘導体の調製における中間体としての５－（（ハロフェニル）－３－ハロ－ピリジン－２－イル）－ニトリル誘導体
JP2022035813A Active JP7284309B2 (ja) 2011-06-06 2022-03-09 ［（５－（ハロフェニル）－３－ヒドロキシピリジン－２－カルボニル）－アミノ］アルカン酸誘導体の調製における中間体としての５－（（ハロフェニル）－３－ハロ－ピリジン－２－イル）－ニトリル誘導体
JP2023081959A Active JP7685552B2 (ja) 2011-06-06 2023-05-18 ［（５－（ハロフェニル）－３－ヒドロキシピリジン－２－カルボニル）－アミノ］アルカン酸誘導体の調製における中間体としての５－（（ハロフェニル）－３－ハロ－ピリジン－２－イル）－ニトリル誘導体

Country Status (23)

Country Link
US (6) US9145366B2 (enExample)
EP (5) EP3290404B1 (enExample)
JP (6) JP6290781B2 (enExample)
KR (5) KR102000485B1 (enExample)
CN (1) CN106518759B (enExample)
AU (4) AU2012268426B2 (enExample)
CA (2) CA2838194C (enExample)
CY (4) CY1117177T1 (enExample)
DK (4) DK3683209T3 (enExample)
ES (4) ES2900572T3 (enExample)
HR (4) HRP20151416T1 (enExample)
HU (4) HUE034975T2 (enExample)
IL (1) IL229775A (enExample)
LT (3) LT3000808T (enExample)
MX (2) MX337216B (enExample)
NO (1) NO2686520T3 (enExample)
PL (4) PL3290404T3 (enExample)
PT (4) PT3290404T (enExample)
RS (3) RS54517B1 (enExample)
RU (2) RU2602083C2 (enExample)
SI (4) SI2718265T1 (enExample)
SM (3) SMT202000061T1 (enExample)
WO (1) WO2012170377A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ601730A (en) 2006-06-26 2014-04-30 Akebia Therapeutics Inc Prolyl hydroxylase inhibitors and methods of use
NO2686520T3 (enExample) 2011-06-06 2018-03-17
SMT202400092T1 (it) 2013-06-13 2024-05-14 Akebia Therapeutics Inc Composizioni e metodi per il trattamento dell'anemia
EP3578546A1 (en) 2013-11-15 2019-12-11 Akebia Therapeutics Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
WO2016034108A1 (zh) 2014-09-02 2016-03-10 广东东阳光药业有限公司 喹啉酮类化合物及其应用
HK1247201A1 (zh) 2015-01-23 2018-09-21 阿克比治疗有限公司 2-(5-(3-氟苯基)-3-羟基吡啶甲醯胺)乙酸的固体形式、其组合物及用途
EP3270922A4 (en) * 2015-03-20 2018-08-01 Akebia Therapeutics Inc. Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors
CN106146395B (zh) 2015-03-27 2019-01-01 沈阳三生制药有限责任公司 3-羟基吡啶化合物、其制备方法及其制药用途
PL3277270T3 (pl) 2015-04-01 2022-02-14 Akebia Therapeutics, Inc. Kompozycje i sposoby leczenia niedokrwistości
US10703724B2 (en) 2016-12-13 2020-07-07 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystalline forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino} acetic acid and processes for preparation thereof
IL269623B2 (en) * 2017-03-29 2025-05-01 Emerald Health Pharmaceuticals Inc Cannabidiol derivatives as inhibitors of the hif prolyl hydroxylases activity
WO2019028150A1 (en) 2017-08-01 2019-02-07 Akebia Therapeutics, Inc. COMPOSITIONS FOR USE IN METHODS OF TREATING HEMOGLOBINOPATHIES
CA3097219A1 (en) * 2018-05-09 2019-11-14 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
WO2020075199A1 (en) 2018-10-12 2020-04-16 Mylan Laboratories Limited Polymorphic forms of vadadustat
WO2020108941A1 (en) 2018-11-28 2020-06-04 Sandoz Ag Multi-component crystals of an orally available hif prolyl hydroxylase inhibitor
US12134600B2 (en) 2019-04-26 2024-11-05 Kaneka Corporation Method for producing a vadadustat intermediate
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
CN111087343B (zh) * 2019-11-29 2022-02-18 万华化学集团股份有限公司 一种羟基吡啶配体及其制备方法和催化应用
US12612367B2 (en) 2019-12-10 2026-04-28 Akebia Therapeutics, Inc. Method for producing nitrogen-containing heteroarylcarboxamide acetic acid derivative
EP4094832A4 (en) 2020-01-24 2024-04-17 APS Japan Co., Ltd. Photocatalyst unit and mask provided with photocatalyst unit
WO2022006427A1 (en) 2020-07-02 2022-01-06 Akebia Therapeutics, Inc. Manufacturing process for 3,5-dichloropicolinonitrile for synthesis of vadadustat
GB202011431D0 (en) * 2020-07-23 2020-09-09 Johnson Matthey Plc Polymorphs of vadadustat and methods for preparing the polymorphs
EP4447963A1 (en) 2021-12-17 2024-10-23 Akebia Therapeutics Inc. Selective phd1 inhibitor compounds, compositions, and methods of use
WO2024165507A1 (en) 2023-02-06 2024-08-15 Institut National de la Santé et de la Recherche Médicale Use of hif-1α stabilizing agents for the treatment of type i interferonopathies

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3655679A (en) * 1969-06-25 1972-04-11 Merck & Co Inc Certain aryl pyridine carboxylic acid derivatives
US3703582A (en) * 1970-04-20 1972-11-21 Merck & Co Inc Aryl pyridine carboxylic acids in the treatment of inflammation
US3894920A (en) 1971-12-21 1975-07-15 Sagami Chem Res Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives
US4016287A (en) 1972-07-17 1977-04-05 Boehringer Ingelheim Gmbh Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof
TW219933B (enExample) 1990-02-26 1994-02-01 Lilly Co Eli
US5405613A (en) 1991-12-11 1995-04-11 Creative Nutrition Canada Corp. Vitamin/mineral composition
TW352384B (en) 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
DE4219158A1 (de) 1992-06-11 1993-12-16 Thomae Gmbh Dr K Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
EP0650960B1 (de) 1993-11-02 1997-03-05 Hoechst Aktiengesellschaft Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
ATE149486T1 (de) 1993-11-02 1997-03-15 Hoechst Ag Substituierte heterocyclische carbonsäureamide, ihre herstellung und ihre verwendung als arzneimittel
TW406076B (en) 1993-12-30 2000-09-21 Hoechst Ag Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
DE4410480A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE4410423A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US5789426A (en) 1995-01-20 1998-08-04 Cornell Research Foundation, Inc. Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
JPH09221476A (ja) 1995-12-15 1997-08-26 Otsuka Pharmaceut Co Ltd 医薬組成物
EP0900202A1 (de) 1996-04-30 1999-03-10 Hoechst Aktiengesellschaft 3-alkoxypyridin-2-carbonsäureamidester, ihre herstellung und ihre verwendung als arzneimittel
DE19620041A1 (de) 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE19650215A1 (de) 1996-12-04 1998-06-10 Hoechst Ag 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
US6420427B1 (en) 1997-10-09 2002-07-16 Ono Pharmaceutical Co., Ltd. Aminobutyric acid derivatives
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
ES2224620T3 (es) 1998-03-23 2005-03-01 Aventis Pharmaceuticals Inc. Derivados de piperidinilo y n-aminopiperidinilo.
US6159379A (en) 1999-05-04 2000-12-12 Baker Hughes Incorporated Organic ammonium salts for the removal of water soluble organics in produced water
JP2001048786A (ja) 1999-08-05 2001-02-20 Yamanouchi Pharmaceut Co Ltd 三環式ヘテロアリール誘導体
US6589758B1 (en) 2000-05-19 2003-07-08 Amgen Inc. Crystal of a kinase-ligand complex and methods of use
US6849718B2 (en) 2001-03-20 2005-02-01 Dana Farber Cancer Institute, Inc. Muteins of hypoxia inducible factor alpha and methods of use thereof
US6855510B2 (en) 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
WO2002074981A2 (en) 2001-03-21 2002-09-26 Isis Innovation Ltd. Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase
SE0101327D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab New crystalline forms
US6566088B1 (en) 2001-10-04 2003-05-20 Board Of Regents, The University Of Texas System Prolyl-4-hydroxylases
GB0124941D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
CN102526045A (zh) 2001-12-06 2012-07-04 法布罗根股份有限公司 提高内源性红细胞生成素(epo)的方法
WO2003097040A1 (en) 2002-05-17 2003-11-27 Celgene Corporation Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
EP1545538A2 (en) * 2002-08-29 2005-06-29 Merck & Co., Inc. N-biarylmethyl aminocycloalkanecarboxamide derivatives
US7778779B2 (en) 2002-10-16 2010-08-17 Isis Innovation Limited Method of identifying a chemical entity which is a hydroxylase modulator
CA2506799A1 (en) 2002-11-21 2004-06-10 Eli Lilly And Company Mixed lineage kinase modulators
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US7183287B2 (en) 2003-04-03 2007-02-27 Pharmacia Corporation Substituted pyrimidinones
WO2005007192A2 (en) 2003-06-06 2005-01-27 Fibrogen, Inc. Cytoprotection through the use of hif hydroxylase inhibitors
KR100932169B1 (ko) 2003-06-06 2009-12-16 피브로겐, 인크. 질소-함유 헤테로아릴 화합물 및 내인성 적혈구생성소의증가에서의 그들의 사용
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
GB0314129D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
WO2005108370A1 (ja) 2004-04-16 2005-11-17 Ajinomoto Co., Inc. ベンゼン化合物
AU2005250412B2 (en) 2004-05-28 2009-09-17 Fibrogen, Inc. HIF prolyl hydroxylase activity assay
EP1771418A2 (en) 2004-05-31 2007-04-11 Tanabe Seiyaku Co., Ltd. Large conductance calcium-activated k channel opener
EP1771169A1 (en) 2004-07-14 2007-04-11 PTC Therapeutics, Inc. Methods for treating hepatitis c
TW200616969A (en) 2004-09-17 2006-06-01 Tanabe Seiyaku Co Imidazole compound
WO2006084210A2 (en) 2005-02-04 2006-08-10 Regents Of The University Of California, San Diego Hif modulating compounds and methods of use thereof
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
US20060276477A1 (en) 2005-06-06 2006-12-07 Fibrogen, Inc. Treatment method for anemia
ATE470439T1 (de) 2005-06-15 2010-06-15 Fibrogen Inc Verwendung von hif 1alfa modulatoren zur behandlung von krebs
WO2007033216A2 (en) 2005-09-12 2007-03-22 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
WO2007038571A2 (en) 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
WO2007047194A2 (en) 2005-10-11 2007-04-26 Dana-Farber Cancer Institute, Inc. Methods for treating mitf-related disorders
AU2006326662B2 (en) 2005-12-09 2011-07-28 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof
MX2008008608A (es) 2006-01-09 2009-03-04 Btg Int Ltd Moduladores de factor i inducible por hipoxia y usos relacionados.
WO2007082899A1 (en) 2006-01-17 2007-07-26 Vib Vzw Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
JP2009523812A (ja) 2006-01-19 2009-06-25 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド 融合へテロ二環式キナーゼ阻害剤
JP4801451B2 (ja) 2006-01-19 2011-10-26 株式会社日立ハイテクノロジーズ 走査電子顕微鏡等に用いる電子銃の制御装置及び制御方法
ITMI20060179A1 (it) 2006-02-02 2007-08-03 Abiogen Pharma Spa Procedimento per la risoluzione di miscele racemiche e complesso diastereoisomerico di un agente risolvente e di unantiomero di interesse
US7625927B2 (en) 2006-02-27 2009-12-01 Alcon Research, Ltd. Method of treating glaucoma
AR059733A1 (es) 2006-03-07 2008-04-23 Smithkline Beecham Corp Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
WO2007136990A2 (en) 2006-05-16 2007-11-29 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
JO2934B1 (en) 2006-06-23 2015-09-15 سميث كلاين بيتشام كوربوريشن Prolyl hydroxylase inhibitors
NZ601730A (en) * 2006-06-26 2014-04-30 Akebia Therapeutics Inc Prolyl hydroxylase inhibitors and methods of use
TW200845994A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: prolyl hydroxylase inhibitors
TW200845991A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: hydroxylase inhibitors
ES2446418T3 (es) 2007-04-18 2014-03-07 Amgen, Inc Derivados de indanona que inhiben la prolil hidroxilasa
AU2008241503A1 (en) 2007-04-18 2008-10-30 Merck Sharp & Dohme Corp. Novel 1,8-naphthyridine compounds
US8030346B2 (en) 2007-05-04 2011-10-04 Amgen Inc. Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity
JP5349462B2 (ja) 2007-05-16 2013-11-20 メルク・シャープ・アンド・ドーム・コーポレーション スピロインダロン
EP2148877A2 (en) 2007-05-18 2010-02-03 Bayer Schering Pharma AG Inhibitors of hypoxia inducible factor (hif) useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2009020119A1 (ja) 2007-08-06 2009-02-12 Senju Pharmaceutical Co., Ltd. ＨＩＦ－１αおよびＨＩＦ－２α発現阻害物質含有医薬
TW200908984A (en) 2007-08-07 2009-03-01 Piramal Life Sciences Ltd Pyridyl derivatives, their preparation and use
CA2696725A1 (en) 2007-08-10 2009-03-26 Crystalgenomics, Inc. Pyridine derivatives and methods of use thereof
WO2009035534A2 (en) 2007-09-07 2009-03-19 The Cleveland Clinic Foundation Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif)
WO2009039323A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009039321A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009043093A1 (en) 2007-10-04 2009-04-09 Newsouth Innovations Pty Limited Hif inhibition
WO2009049112A1 (en) 2007-10-10 2009-04-16 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009067790A1 (en) 2007-11-26 2009-06-04 Uti Limited Partnership STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION
US20100305154A1 (en) 2007-11-30 2010-12-02 Glaxosmithkline Llc Prolyl Hydroxylase Inhibitors
WO2009073497A2 (en) 2007-11-30 2009-06-11 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
US8269008B2 (en) 2007-12-03 2012-09-18 Fibrogen, Inc. Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions
EP2240178A4 (en) 2007-12-19 2011-10-26 Glaxosmithkline Llc PROLYLHYDROXYLASEHEMMER
WO2009086592A1 (en) 2008-01-04 2009-07-16 Garvan Institute Of Medical Research Method of increasing metabolism
EP2252619B1 (en) 2008-01-11 2013-10-09 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
ES2546213T3 (es) * 2008-03-03 2015-09-21 Novartis Ag Compuestos y composiciones como moduladores de la actividad de TLR
US20090228298A1 (en) * 2008-03-04 2009-09-10 The General Electric Company System and method of morphology feature analysis of physiological data
KR20100134680A (ko) * 2008-03-20 2010-12-23 포레스트 래보러토리즈 홀딩스 리미티드 스테아로일-ｃｏａ 불포화효소의 저해물질로서 신규한 피페리딘 유도체
AR071997A1 (es) 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
BRPI0916233A2 (pt) 2008-07-23 2018-03-13 F.Hoffman-La Roche Ag compostos heterocíclicos antivirais
EP2324006B1 (en) 2008-09-15 2014-08-13 Kasina Laila Innova Pharmaceuticals Private Ltd. Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers
CN102272117B (zh) 2008-11-14 2015-06-17 菲布罗根有限公司 作为hif羟化酶抑制剂的苯并噻喃衍生物
PT2415771E (pt) 2009-03-31 2013-10-03 Kissei Pharmaceutical Derivado de indolizina e sua utilização para fins médicos
ES2782999T3 (es) 2009-11-06 2020-09-16 Aerpio Therapeutics Inc Composiciones y métodos para tratar la colitis
NO2686520T3 (enExample) 2011-06-06 2018-03-17
EP3251671A1 (en) 2011-06-06 2017-12-06 Akebia Therapeutics Inc. Compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
US20130022974A1 (en) 2011-06-17 2013-01-24 The Regents Of The University Of Michigan Dna methylation profiles in cancer
CA2842730C (en) 2011-07-22 2018-08-21 Beijing Betta Pharmaceuticals Co., Ltd Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof
EP2983674A4 (en) 2013-04-08 2017-05-10 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
SMT202400092T1 (it) 2013-06-13 2024-05-14 Akebia Therapeutics Inc Composizioni e metodi per il trattamento dell'anemia
CN105979779A (zh) 2013-08-16 2016-09-28 俄亥俄州国家创新基金会 调整dna甲基化的组合物和方法
EP3578546A1 (en) 2013-11-15 2019-12-11 Akebia Therapeutics Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
CA2937349A1 (en) 2014-01-23 2015-07-30 Akebia Therapeutics, Inc. Compositions and methods for treating ocular diseases
HK1247201A1 (zh) 2015-01-23 2018-09-21 阿克比治疗有限公司 2-(5-(3-氟苯基)-3-羟基吡啶甲醯胺)乙酸的固体形式、其组合物及用途
EP3270922A4 (en) 2015-03-20 2018-08-01 Akebia Therapeutics Inc. Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors
PL3277270T3 (pl) 2015-04-01 2022-02-14 Akebia Therapeutics, Inc. Kompozycje i sposoby leczenia niedokrwistości
CA3097219A1 (en) 2018-05-09 2019-11-14 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid

Also Published As

Publication number Publication date
NO2686520T3 (enExample) 2018-03-17
KR102293016B1 (ko) 2021-08-26
CN106518759A (zh) 2017-03-22
CY1119605T1 (el) 2018-04-04
PL3683209T3 (pl) 2022-02-21
US20190375713A1 (en) 2019-12-12
US20120309977A1 (en) 2012-12-06
SMT201700534T1 (it) 2018-01-11
DK3683209T3 (da) 2021-12-06
JP7284309B2 (ja) 2023-05-30
PL3000808T3 (pl) 2018-03-30
HUE048044T2 (hu) 2020-05-28
KR102032864B1 (ko) 2019-10-16
KR20190032617A (ko) 2019-03-27
JP7685552B2 (ja) 2025-05-29
SMT202000061T1 (it) 2020-03-13
HRP20211916T1 (hr) 2022-03-18
US9776969B2 (en) 2017-10-03
PT3290404T (pt) 2020-02-19
EP2718265A1 (en) 2014-04-16
EP3000808A1 (en) 2016-03-30
MX2013014228A (es) 2014-03-26
CA2838194C (en) 2022-01-11
LT3000808T (lt) 2018-01-25
RU2016139352A3 (enExample) 2020-01-27
US20150361043A1 (en) 2015-12-17
KR102059366B1 (ko) 2019-12-26
LT3683209T (lt) 2022-01-10
PT3000808T (pt) 2017-11-23
SMT201600013B (it) 2016-02-25
AU2018250355B2 (en) 2020-04-09
US20170362178A1 (en) 2017-12-21
JP7039682B2 (ja) 2022-03-22
CY1122639T1 (el) 2021-03-12
JP2023103414A (ja) 2023-07-26
HUE034975T2 (en) 2018-05-02
HRP20151416T1 (hr) 2016-03-25
PL3290404T3 (pl) 2020-06-01
HRP20200197T1 (hr) 2020-05-15
US10246416B2 (en) 2019-04-02
EP2718265A4 (en) 2014-11-19
NZ618570A (en) 2015-07-31
US11267785B2 (en) 2022-03-08
US20230002323A1 (en) 2023-01-05
CY1117177T1 (el) 2017-04-05
SI2718265T1 (sl) 2016-03-31
SI3000808T1 (en) 2018-02-28
WO2012170377A1 (en) 2012-12-13
JP2018111697A (ja) 2018-07-19
AU2017202414B2 (en) 2018-07-19
US20210122715A1 (en) 2021-04-29
PT3683209T (pt) 2021-12-15
KR20190141805A (ko) 2019-12-24
AU2020204528B2 (en) 2022-07-14
DK2718265T3 (en) 2016-01-25
AU2012268426B2 (en) 2017-02-16
PL2718265T3 (pl) 2016-04-29
US10738010B2 (en) 2020-08-11
EP3290404B1 (en) 2019-12-11
JP6510094B2 (ja) 2019-05-08
RU2764667C2 (ru) 2022-01-19
EP4026829A1 (en) 2022-07-13
AU2020204528A1 (en) 2020-07-30
EP3000808B1 (en) 2017-09-27
ES2559850T3 (es) 2016-02-16
PT2718265E (pt) 2016-02-15
MX347709B (es) 2017-05-10
KR20190031593A (ko) 2019-03-26
RU2013158640A (ru) 2015-07-20
JP2014522409A (ja) 2014-09-04
RU2016139352A (ru) 2018-12-13
CY1124874T1 (el) 2022-11-25
RS59902B1 (sr) 2020-03-31
US9145366B2 (en) 2015-09-29
CA2838194A1 (en) 2012-12-13
EP3683209B1 (en) 2021-11-10
HUE026096T2 (en) 2016-05-30
DK3000808T3 (da) 2017-11-27
JP2019123741A (ja) 2019-07-25
HK1216173A1 (en) 2016-10-21
IL229775A (en) 2016-06-30
EP3290404A1 (en) 2018-03-07
JP2021059573A (ja) 2021-04-15
AU2012268426A1 (en) 2014-01-09
LT3290404T (lt) 2020-02-25
HUE057571T2 (hu) 2022-05-28
MX337216B (es) 2016-02-18
ES2771232T3 (es) 2020-07-06
DK3290404T3 (da) 2020-02-17
CN106518759B (zh) 2019-07-30
AU2017202414A1 (en) 2017-05-04
CN103717575A (zh) 2014-04-09
HRP20171740T1 (hr) 2018-03-09
HK1196616A1 (zh) 2014-12-19
KR102000485B1 (ko) 2019-07-16
ES2900572T3 (es) 2022-03-17
SI3683209T1 (sl) 2022-03-31
EP2718265B1 (en) 2015-12-16
KR102171315B1 (ko) 2020-10-28
JP6816195B2 (ja) 2021-01-20
EP3683209A1 (en) 2020-07-22
RU2602083C2 (ru) 2016-11-10
ES2647602T3 (es) 2017-12-22
KR20140037192A (ko) 2014-03-26
JP2022081597A (ja) 2022-05-31
RS54517B1 (sr) 2016-06-30
HK1252109A1 (en) 2019-05-17
SI3290404T1 (sl) 2020-03-31
RS56580B1 (sr) 2018-02-28
CA3135440A1 (en) 2012-12-13
AU2018250355A1 (en) 2018-11-08
KR20200121911A (ko) 2020-10-26

Similar Documents

Publication Publication Date Title
JP7284309B2 (ja) ［（５－（ハロフェニル）－３－ヒドロキシピリジン－２－カルボニル）－アミノ］アルカン酸誘導体の調製における中間体としての５－（（ハロフェニル）－３－ハロ－ピリジン－２－イル）－ニトリル誘導体
HK40078298A (en) Process for preparing n-[[5-(3-chlorophenyl)-3-hydroxy-2-pyridinyl]carbonyl]-glycine from 5-(3-chlorophenyl)-3-hydroxy-2-pyridine carboxylic acid
CN103717575B (zh) 用于制备[(3-羟基吡啶-2-羰基)氨基]链烷酸、酯和酰胺的方法
HK40033676B (en) Process for preparing [(5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl)-amino]acetic acid from 5-((3-chlorophenyl)-3-chloro-pyridin-2-yl)-nitrile, and process for preparing 5-((halophenyl)-3-halo-pyridin-2-yl)-nitrile derivatives
HK40033676A (en) Process for preparing [(5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl)-amino]acetic acid from 5-((3-chlorophenyl)-3-chloro-pyridin-2-yl)-nitrile, and process for preparing 5-((halophenyl)-3-halo-pyridin-2-yl)-nitrile derivatives
HK1252109B (en) 5-((halophenyl)-3-halo-pyridin-2-yl)-nitrile derivatives as intermediates in the preparation of [(5-(halophenyl)-3-hydroxypyridine-2-carbonyl)-amino]alkanoic acid derivatives
HK1216173B (en) 5-((halophenyl)-3-hydroxy-pyridin-2-yl)-carboxylic acid derivatives as intermediates for the preparation of carbonylamino alkanoic acids, esters and amides thereof
HK1196616B (en) Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150522

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160308

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160809

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170627

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170922

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171222

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180109

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180208

R150 Certificate of patent or registration of utility model

Ref document number: 6290781

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250